Journal article

Trends in serotypes and sequence types among cases of invasive pneumococcal disease in Scotland, 1999-2010

Karen E Lamb, Stefan Flasche, Mathew Diggle, Donald Inverarity, David Greenhalgh, Johanna M Jefferies, Andrew Smith, Giles FS Edwards, Barbara Denham, Jim McMenamin, Eisin McDonald, Tim J Mitchell, Stuart C Clarke, Chris Robertson

Vaccine | ELSEVIER SCI LTD | Published : 2014

Abstract

INTRODUCTION: The 7-valent pneumococcal conjugate vaccine (Prevenar(®), Wyeth; PCV7) was introduced to the UK paediatric immunisation schedule in 2006. This study investigates trends in serotypes and multi locus sequence types (STs) among cases of invasive pneumococcal disease (IPD) in Scotland prior to, and following, the introduction of PCV7. METHODS: Scottish Invasive Pneumococcal Disease Enhanced Surveillance has records of all cases of IPD in Scotland since 1999. Cases diagnosed from blood or cerebrospinal fluid isolates until 2010 were analysed. Logistic and poisson regression modelling was used to assess trends prior to and following the introduction of PCV7. RESULTS: Prior to PCV7 us..

View full abstract

Grants

Funding Acknowledgements

Conflicts of interest: KEL was funded through an EPSRC CASE studentship with Wyeth Pharmaceuticals.SF and MD have no conflicts to declare. DG has received funding to support a PhD studentship from Wyeth Pharmaceuticals. SCC currently receives unrestricted research funding from Pfizer Vaccines (previously Wyeth Vaccines). JMJ and SCC have received consulting fees from GlaxoSmithKline and have received financial assistance from vaccine manufacturers to attend conferences. All grants and honoraria are paid into accounts within the respective NHS Trusts or Universities, or to independent charities. JMJ, TJM, SCC, AS and GFSE previously received funding from Wyeth Pharmaceuticals for a collaborative project with the Institute of Biological Sciences, University of Glasgow and the Scottish Meningococcal and Pneumococcal Reference Laboratory (2005-2007). BD, JM and EM have no conflicts to declare. CR has received research funding from and has acted as a consultant for Wyeth Pharmaceuticals.